Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Erythema

imatinib mesylate has been researched along with Erythema in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Battistella, M; Dubertret, L; Frémont, G; Gornet, JM; Vignon-Pennamen, MD; Viguier, M1
Duncan, E; Mufti, G; Raj, K1
Matsouka, P; Monastirli, A; Pasmatzi, E; Tsambaos, D1
Ajima, A; Hasegawa, Y; Kojima, H; Nagasawa, T; Takayama, N1
Bakshi, A; Biswas, G; Deshmukh, C; Parikh, PM; Prasad, N; Sastry, PS1
Higashi, T; Kubota, A; Matsuura, A; Mizobe, T; Morimoto, H; Mouri, F; Ohta, T; Sugito, M; Tanaka, Y; Tsukada, J1

Other Studies

6 other study(ies) available for imatinib mesylate and Erythema

ArticleYear
Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
    Archives of dermatology, 2008, Volume: 144, Issue:10

    Topics: Benzamides; Biopsy, Needle; Drug Eruptions; Erythema; Follow-Up Studies; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyloric Antrum; Pyrimidines; Risk Assessment; Stomach Neoplasms; Syndrome

2008
Erythema following imatinib mesylate.
    British journal of haematology, 2003, Volume: 122, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzamides; Drug Eruptions; Enzyme Inhibitors; Erythema; Humans; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2003
Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
    Acta dermato-venereologica, 2003, Volume: 83, Issue:5

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Erythema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methylprednisolone; Middle Aged; Piperazines; Pityriasis; Pyrimidines

2003
[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Erythema; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines

2003
Dermatological toxicity of imatinib mesylate.
    The Journal of the Association of Physicians of India, 2005, Volume: 53

    Topics: Adult; Benzamides; Erythema; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2005
[Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:11

    Topics: Antineoplastic Agents; Basophils; Benzamides; Erythema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Leukopenia; Middle Aged; Piperazines; Pyrimidines; Severity of Illness Index

2005